Get the Daily Brief
Latest Biotech News
Efti Phase III Halts – Immutep Trial Discontinued for Futility
Immutep halted its phase III TACTI‑004 trial of eftilagimod alfa (IMP‑321, efti) in first‑line non‑small‑cell lung cancer after an independent data monitoring committee recommended stopping for...
FDA Tentatively Clears Lutathera Copy: Lantheus vs Novartis Patent Fight
The FDA issued a tentative approval for Lantheus’ ANDA for PNT2003, a potential generic version of Novartis’ radioligand Lutathera (lutetium Lu 177 dotatate), while active patent litigation...
Cadonilimab Combo Improves Outcomes in Advanced Cervical Cancer
COMPASSION‑16 Phase 3 results showed that adding cadonilimab to first‑line chemotherapy—with or without bevacizumab—produced meaningful clinical benefit in advanced cervical cancer. The trial...
IL‑7/IL‑15/IL‑21 Scaffold Recharges CAR‑T Cells: Longer‑Lived Cells in Mice
Researchers at Albert Einstein College of Medicine reported a modular cytokine‑fusion scaffold (HCW9206) that links IL‑7, IL‑15 and IL‑21 and produces CAR‑T cells enriched in long‑lived T memory...
Antibody‑siRNA Conjugate Reaches Muscle – Early Human Data in Myotonic Dystrophy
Delpacibart etedesiran (del‑desiran, AOC‑1001), an antibody‑siRNA conjugate designed to deliver siRNA to muscle, showed target engagement and DMPK knockdown in early clinical testing for myotonic...
Engineered Bacteria Boost Doxorubicin Yield – Production Barrier Overcome
An international research consortium reported engineering a bacterial strain that overcomes long‑standing molecular bottlenecks in doxorubicin biosynthesis, enabling markedly higher yields of the...
Eurofins Pushes ADC Manufacturing: Expression Platform and AI Formulation Tools
Eurofins CDMO Alphora announced participation in a NextGen ADC consortium to develop high‑yield expression vectors with engineered peptide linker tags, and separately launched an AI‑powered salt...
GSK Backs UK Digital‑Twin Center to Model Lungs, Liver and Kidneys
GSK, Imperial College London and the University of Oxford launched the Modelling‑Informed Medicine Centre (MiMeC) with £11 million to build digital twins of organs—lung, liver and kidney—to inform...
China Clears First Commercial Brain Implant for Spinal‑Cord Injury
China approved Neuracle Medical Technology’s coin‑sized, wireless cortical brain‑computer interface (BCI) for commercial use in patients with spinal cord injury—the first national clearance of its...
Lucence, A*STAR and NCCS Launch S$6M Multiomic Cancer Profiling Project
Lucence Diagnostics, A*STAR’s DxD Hub and the National Cancer Centre Singapore launched UNITED 2.0, a S$6 million collaboration to develop a clinical, AI‑augmented whole‑genome and...
FDA gives tentative nod to Lantheus’ Lutathera copy — patent fight looms
The FDA issued a tentative approval for Lantheus’ ANDA for PNT2003, a generic version of Novartis’ radioligand Lutathera (lutetium Lu 177 dotatate). Lantheus, Novartis and Curium are now locked in...
Disitamab vedotin posts >50% response in urothelial cancer...her2 low responds too
New phase 2 results from the RC48G001 trial showed disitamab vedotin (DV), a HER2‑targeted ADC with an MMAE payload, produced confirmed overall response rates of 54.9% in HER2‑positive and 52.6%...
Immutep’s LAG‑3 program halted — stock collapses, company scrambles
Immutep halted its Phase III TACTI‑004 trial of eftilagimod alfa (efti, IMP‑321) in first‑line non‑small‑cell lung cancer after an interim futility analysis, sending the company’s shares...
Ultragenyx gene therapy hits a primary endpoint in rare ammonia disorder trial
Ultragenyx reported that its gene therapy candidate for ornithine transcarbamylase (OTC) deficiency met one of two primary endpoints in a Phase 3 trial involving 37 patients with blood ammonia...
Vima ups Series A with $40m extension to push movement‑disorder candidates
Vima raised a $40 million extension to its Series A, taking total financing to $100 million to complete two Phase II trials in isolated dystonia and Parkinson’s disease. Investors in the tranche...
Engineered bacteria clear decades‑old bottleneck in doxorubicin manufacturing
An international consortium reported in Nature Communications that engineered a bacterial strain which resolves long‑standing molecular bottlenecks in the biosynthesis of the anthracycline...
Cytokine‑fusion scaffold produces long‑lived CAR‑T cells in preclinical models
Researchers at Albert Einstein College of Medicine described a manufacturing innovation that links IL‑7, IL‑15 and IL‑21 into a single protein scaffold (HCW9206) used during CAR‑T production. In...
Antibody‑siRNA conjugate reaches muscle—early DM1 trial shows target knockdown
The antibody‑siRNA conjugate delpacibart etedesiran (del‑desiran, AOC‑1001) demonstrated muscle delivery and DMPK mRNA depletion in Phase I/II MARINA trial data reported in NEJM. Investigators led...
China approves first commercial brain implant for spinal‑injury patients
Shanghai‑based Neuracle Medical Technology received Chinese regulatory approval to commercialize a coin‑sized wireless cortical brain‑computer interface (BCI) for patients with spinal cord...
Senolytic strategy clears therapy‑resistant cells in pancreatic cancer models
Researchers unveiled a senolytic therapeutic approach for pancreatic ductal adenocarcinoma (PDAC) that targets senescent tumor‑supporting cells and the KRAS–RB1 interaction, producing tumor...